In order to evaluate potential associations between neurosin, α-synuclein and the established AD biomarkers, as additional indicators of disease severity, we compiled AD biomarker data from a subset of the individuals included in our study and of whom the CSF had undergone routine analysis for Aβ42, t-tau and p-tau. The gene discussed is MAPT; the disease is Alzheimer disease.